Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance

References

• Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288–1295
   PubMed Web of Science ®Google Scholar
• Harrison P, Frelinger AL, 3rd, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120: 323–336
   PubMed Web of Science ®Google Scholar
• Breddin HK. Can platelet aggregometry be standardized?. Platelets 2005; 16: 151–158
   PubMed Web of Science ®Google Scholar
• Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009; 119: 2625–2632
   PubMed Web of Science ®Google Scholar
• Jilma B. Platelet function analyzer – PFA-100: A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152–163
   PubMed Web of Science ®Google Scholar
• Golanski J, Pluta J, Baraniak J, Watala C. Limited usefulness of the PFA-100 for the monitoring of ADP receptors antagonists-in vitro experience. Clin Chem Lab Med 2004; 42: 25–29
   PubMed Web of Science ®Google Scholar
• Mani H, Linnemann B, Luxembourg B, Kirchmayr K, Lindhoff-Last E. Response to aspirin and clopidogrel monitored with different platelet function methods. Platelets 2006; 17: 303–310
   PubMed Web of Science ®Google Scholar
• Raman S, Jilma BJ. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J Thromb Haemost 2004; 2: 2278–2279
   PubMed Web of Science ®Google Scholar
• Edwards A, Jakubowski JA, Rechner AR, Sugidachi A, Harrison P, Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y(12) blockade and influence of anticoagulant. Platelets. 2012;23:106–115
   Google Scholar
• Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542–549
   PubMed Web of Science ®Google Scholar
• Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420–2425
   PubMed Web of Science ®Google Scholar
• Linnemann B, Schwonberg J, Rechner A, Mani H, Lindhoff-Last E. Assessment of clopidogrel non-response by the PFA-100 system using the new cartridge INNOVANCE PFA P2Y. Ann Hematol 2010; 89: 597–605
   PubMed Web of Science ®Google Scholar
• Koessler J, Kobsar AL, Rajkovic MS, Schafer A, Flierl U, Pfoertsch S, Bauersachs J, Steigerwald U, Rechner AR, Walter U. The new INNOVANCE PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition. Platelets 2011; 22: 19–25
   Web of Science ®Google Scholar
• Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intralpatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85–92
   PubMed Web of Science ®Google Scholar
• Kim CW, Yun JW, Bae IH, Park YH, Jeong YS, Park JW, Chung JH, Park YH, Lim KM. Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo. Thromb Res 2011; 127: 565–570
   PubMed Web of Science ®Google Scholar
• Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, Kubica A, Grabczewska Z, Navarese EP, Andreotti F, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011; 22: 579–587
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–933
   PubMed Web of Science ®Google Scholar
• Tsantes A, Dimoula A, Bonovas S, Mantzios G, Tsirigotis P, Zoi K, Kalamara E, Kardoulaki A, Sitaras N, Travlou A, et al. The role of the Platelet Function Analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis. Thrombosis Res 2010; 125: 142–146
   PubMed Web of Science ®Google Scholar
• Labarthe B, Theroux P, Angioi M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005; 46: 638–645
   PubMed Web of Science ®Google Scholar
• Kaiser AF, Neubauer H, Franken CC, Krüger JC, Mügge A, Meves SH, Which is the best anticoagulant for whole blood aggregometry platelet function testing? Comparison of six anticoagulants and diverse storage conditions. Platelets. 2011 Oct 14. [Epub ahead of print]
   Google Scholar
• Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009; 20: 7–11
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Bouman H, Breet N, Ten Berg JM, Hackeng CM. The Cone and Platelet analyzer is not suitable to monitor clopidogrel therapy: A comparison with the flowcytometric VASP assay and optical aggregometry. Thrombosis Res 2010; 126: 44–49
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Panzer S, Jilma B. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. Platelets 2008; 19: 551–554
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Bruno V, Willheim M, Hübl W, Wojta J, Huber K. Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: Does standardisation matter?. Thromb Haemost 2012; 107: 538–544
   PubMed Web of Science ®Google Scholar
• Bruton A, Conway JH, Holgate ST. Reliability: What is it and how is it measured?. Physiotherapy 2000; 86: 94–99
   Google Scholar
• Remijn JA, Wu YP, Jeninga EH, Isseldijk MJ, van Willigen G, de Groot PG, Sixma JJ, Nurden AT, Nurden P. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002; 22: 686–691
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Zighetti LM, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J, Ruggeri ZM. Molecular basis of defective signal transduction in platelet P2Y12 receptor a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 1978–1983
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST –STENTING Study. J Am Coll Cardiol 2005; 46: 1820–1826
   PubMed Web of Science ®Google Scholar
• Tsantes A, Mantzios G, Giannopoulou V, Tsirigotis P, Bonovas S, Rapti E, Mygiaki E, Kartasis Z, Sitaras NM, Dervenoulas J, et al. Monitoring aspirin treatment in patients with thrombocytosis: Comparison of the platelet function analyzer (PFA)-100 with optical aggregometry. Thromb Res 2008; 123: 100–107
   PubMed Web of Science ®Google Scholar
• Gachet C, Cazenave JP, Ohlmann P, Bouloux C, Defreyn G, Driot F, Lasne D, Fiemeyer A, Chatellier G, Chammas C. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PCE1. Biochem Pharmacol 1990; 40: 2683–2687
   PubMed Web of Science ®Google Scholar
• Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295–302
   PubMed Web of Science ®Google Scholar
• Heilmann EJ, Kundu SK, Sio R, Garcia G, Gomez R, Christie DJ. Comparison of four commercial citrate blood collection systems for platelet function detected by the PFA-100 system. Thromb Res 1997; 87: 159–164
   PubMed Web of Science ®Google Scholar
• Marshall PW, Williams AJ, Dixon RM, Growcott JW, Warburton S, Armstrong J, Moores J. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 1997; 44: 151–155
   PubMed Web of Science ®Google Scholar
• Lasne D, Fiemeyer A, Chatellier G, Gachet C, Cazenave JP, Ohlmann P, Bouloux C, Defreyn G, Driot F, Maffrand JP. A study of platelet functions with a new analyzer using high shear stress (PFA-100) in patients undergoing coronary artery bypass graft. Thromb Haemost 2000; 84: 794–799
   PubMed Web of Science ®Google Scholar
• Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, Elalamy I. In vitro aspirin resistance detected by PFA-100 closure time: Pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124: 80–85
   PubMed Web of Science ®Google Scholar
• Koessler J, Ehrenschwender M, Kobsar A, Brunner K, Evaluation of the new INNOVANCE® PFA P2Y cartridge in patients with impaired primary haemostasis. Platelets 2011 Dec 20. [Epub ahead of print]
   Google Scholar
• Geisler T, Zürn C, Simonenko R, Rapin M, Kraibooj H, Kilias A, Bigalke B, Stellos K, Schwab M, May AE, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59–66
   PubMed Web of Science ®Google Scholar